Countries China
Harbour BioMed Partners With Lannacheng To Advance Next Generation Radionuclide Drug Conjugates
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...
January 02, 2026 | News
Mabwell Doses First Patient Globally In Phase II Trial Of IL 11 Antibody For Pathological Scarring
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of i...
January 01, 2026 | News
Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI
Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...
December 30, 2025 | News
Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study
Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...
December 30, 2025 | News
EMA CHMP Backs Gotenfia Golimumab Biosimilar Advancing STADA and Bio Thera European Strategy
Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marke...
December 30, 2025 | News
Mabwell Secures US FDA IND Clearance For Anti ST2 Antibody In COPD
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...
December 26, 2025 | News
China Approves First Dual Immunotherapy Neoadjuvant Regimen For MSI H dMMR Colon Cancer
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment o...
December 26, 2025 | News
HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framework
In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH")...
December 25, 2025 | News
Jacobio Pharma Strikes Global Deal With AstraZeneca For Pan KRAS Inhibitor JAB 23E73
Jacobio Pharma announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive ...
December 23, 2025 | News
Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...
December 23, 2025 | News
Alphamab Oncology’s JSKN003 Gains FDA Breakthrough Therapy Designation For Platinum Resistant Ovarian Cancer
Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the...
December 23, 2025 | News
Qihan Biotech Initiates Phase I IIa Dosing Of Allogeneic CAR T Therapy For Refractory Lupus
Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-...
December 22, 2025 | News
Harbour BioMed Enters Global Antibody Collaboration With Bristol Myers Squibb
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...
December 18, 2025 | News
Everest Medicines Secures FDA Approval For LEROCHOL In Hypercholesterolemia
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
December 18, 2025 | News
Most Read
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
